The invention relates to novel inhibitors of phosphodiesterase 1 (PDE1), useful for the treatment of diseases or disorders characterized by disruption of or damage to certain cGMP/PKG mediated pathways (e.g., in cardiac tissue). The invention further relates to pharmaceutical composition comprising the same and methods of treatment of cardiovascular disease and related disorders, e.g., congestive heart disease, atherosclerosis, myocardial infarction, and stroke.本發明係關於磷酸二酯酶1(PDE1)之新穎抑制劑，可用於治療以特定cGMP/PKG介導路徑(如，在心臟組織中)之破壞或損傷為特徵的疾病或病症。本發明復關於包含該抑制劑之藥物組成物及治療心血管疾病及相關病症如鬱血性心臟病、動脈粥樣硬化、心肌梗塞、及中風的方法。
